United States

Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

20 Sep 2017
Change (% chg)

$0.05 (+0.15%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two... (more)


Beta: 1.40
Market Cap(Mil.): $4,134.74
Shares Outstanding(Mil.): 124.92
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 31.91 16.25
EPS (TTM): -- -- --
ROI: -- 15.14 14.87
ROE: -- 16.37 13.89

Exclusive: Prosecutors identify Insys founder as unindicted co-conspirator in opioid case

BOSTON U.S. prosecutors have identified Insys Therapeutics Inc's billionaire founder as an unindicted co-conspirator in a case accusing six former executives and managers of participating in a scheme that involved bribing doctors to prescribe a fentanyl-based drug, according to a court document.

Sep 14 2017

BRIEF-Fresenius SE says Akorn shareholders approved merger

* At yesterday's special meeting, shareholders of Akorn, Inc., have approved merger agreement with fresenius kabi, with 83.9 percent of outstanding shares being voted in favour of transaction. Source text for Eikon: Further company coverage:

Jul 20 2017

BRIEF-Akorn shareholders vote to approve merger agreement with Fresenius Kabi

* Akorn shareholders vote to approve merger agreement with Fresenius Kabi

Jul 19 2017

Exclusive: Mallinckrodt explores sale of generic drugs business - sources

Mallinckrodt Plc is exploring a sale of its generic drug unit, in a deal that could fetch as much as $2 billion and help pivot the specialty pharmaceutical maker toward higher-margin branded drugs, according to people familiar with the matter.

May 30 2017

REFILE-Fresenius vows to take breather after three deals

FRANKFURT, May 12 The head of German healthcare group Fresenius SE said he would abstain from the takeover market for now, after striking three deals worth billions of euros in total since taking over less than a year ago.

May 12 2017

Fresenius ups guidance on growth at generic drugs unit

FRANKFURT German healthcare group Fresenius on Wednesday toned up its earnings guidance for the year as demand for recently launched generic infusion drugs continued to grow at higher-than-expected rates.

May 03 2017

Fresenius ups FY guidance on growth at generic drugs unit

FRANKFURT, May 3 German healthcare group Fresenius SE & Co KGaA on Wednesday lifted its guidance on strong demand in the United States for its generic infusion drugs.

May 03 2017

Deals of the day-Mergers and acquisitions

April 25 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

Apr 25 2017

Fresenius picks up M&A pace with Akorn, Merck KGaA deals

FRANKFURT German healthcare group Fresenius SE & Co KGaA has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros) and the biosimilars arm of Germany's Merck KGaA.

Apr 25 2017

UPDATE 2-Fresenius picks up M&A pace with Akorn, Merck KGaA deals

* Fresenius shares up almost 1 percent (Adds advisers, shares, background, CEO, analyst comments)

Apr 25 2017

Earnings vs. Estimates